You are here:

Archived: belimumab (Benlysta)

Advice

following a full submission

belimumab (Benlysta®) is not recommended for use within NHS Scotland.

Indication under review: Add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g. positive anti-dsDNA and low complement) despite standard therapy.

Belimumab, in addition to standard of care, modestly improved disease control in patients with SLE in two phase III studies.

The submitting company's justification of the treatment's cost in relation to its health benefits was not sufficient and, in addition, the submitting company did not present a sufficiently robust economic case to gain acceptance by SMC.

 

Drug Details

Drug Name: belimumab (Benlysta)
SMC Drug ID: 775/12
Manufacturer: GlaxoSmithKline UK Ltd
Indication: Add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus
BNF Category:
Sub Category: 8.2 Drugs affecting the immune response
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 9 April 2012

Current Advice

Resubmission 8 May 2017

Back